We love to hear from our listeners. Send us a message.

Within about five minutes of conversation with Protalix CFO Eyal Rubin, I learned that he doesn’t bite his tongue about the rigors of biotech business and finance management, which is precisely why I’m eager to talk with him on today’s episode of the podcast. From commercialization deals with big pharma to being about $50 million underwater to swatting away the day trading armchair quarterbacks on Stocktwits, Rubin’s seen a few things and he’s developed more than a few opinions.

On this episode of the Business of Biotech, you'll get a front-row seat to a discussion with a biotech CFO who knows how to put on the blinders, shut out distractions, right the ship and set the course to favorable financial waters. Bringing his years of experience in the CFO role at Teva Pharmaceuticals, Brainstorm Cell Therapeutics, and now, Protalix Biotherapeutics, we bring you Eyal Rubin for a story on big biopharma fiscal recoveries.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Fiscal Turnarounds with Protalix's Eyal Rubin

Business Of Biotech